BAMBUTEROL

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H29N3O5
Molecular Weight	367.44
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C

InChI

InChIKey=ANZXOIAKUNOVQU-UHFFFAOYSA-N

InChI=1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3

HIDE SMILES / InChI

Molecular Formula	C18H29N3O5
Molecular Weight	367.44
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24277179
Curator's Comment: Description was created based on several sources, including https://www.medicines.org.uk/emc/medicine/9574 | http://www.meppo.com/pdf/drugs/2596-BAMBEC-ORAL-SOLUTION-1427211370.pdf | https://www.ncbi.nlm.nih.gov/pubmed/2906603

Bambuterol is an active precursor of the selective beta2-adrenergic agonist terbutaline. Bambuterol is the bis-N,N-dimethyl-carbamate of terbutaline. Bambuterol is a remarkably selective and potent inhibitor of cholinesterase. BAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-2 adrenergic receptor 209 Target ID: CHEMBL210 Sources: https://www.medicines.org.uk/emc/medicine/9574	Agonist 2752
Butyrylcholinesterase 45 Target ID: CHEMBL1914 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2906603 \| https://www.ncbi.nlm.nih.gov/pubmed/25504505	Inhibitor 8504		17.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic obstructive pulmonary disease 175 Sources: https://www.medicines.org.uk/emc/medicine/9574 http://www.meppo.com/pdf/drugs/2596-BAMBEC-ORAL-SOLUTION-1427211370.pdf	Primary		Approved 8583	BAMBEC Approved Use BAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction.
Asthma 244 Sources: https://www.medicines.org.uk/emc/medicine/9574 http://www.meppo.com/pdf/drugs/2596-BAMBEC-ORAL-SOLUTION-1427211370.pdf	Primary		Approved 8583	BAMBEC Approved Use BAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction.

C_max

Value	Dose	Analyte	Population
3.69 nM CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	BAMBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
4.35 nM CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	BAMBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
8.56 nM CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	BAMBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
10.3 nM CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	BAMBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
14.23 nM CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	BAMBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
16.75 nM CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	BAMBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
7.1 nM CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	TERBUTALINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
12.2 nM CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TERBUTALINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
12.17 nM CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	TERBUTALINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
20.4 nM CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TERBUTALINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
16.32 nM CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	TERBUTALINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
31.36 nM CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TERBUTALINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Analyte	Population
37.3 nM × h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	BAMBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
20.1 nM × h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	BAMBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
66.8 nM × h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	BAMBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
55.3 nM × h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	BAMBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
108.6 nM × h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	BAMBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
123.7 nM × h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	BAMBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
208.1 nM × h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	TERBUTALINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
196 nM × h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TERBUTALINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
387.6 nM × h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	TERBUTALINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
350.9 nM × h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TERBUTALINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
556.9 nM × h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	TERBUTALINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
550 nM × h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TERBUTALINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
20.14 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	BAMBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
20.9 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	BAMBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
18.47 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	BAMBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
16.52 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	BAMBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
16.85 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	BAMBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
15.04 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	BAMBUTEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
26.5 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	TERBUTALINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
22.25 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TERBUTALINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
22.46 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	TERBUTALINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
22.81 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TERBUTALINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
22.1 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	TERBUTALINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
22.64 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/10718774/	30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TERBUTALINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
50% EXPERIMENT https://www.ijpsonline.com/articles/formulation-and-evaluation-of-solid-selfemulsifying-drug-delivery-system-of-bambuterol-hydrochloride.pdf			BAMBUTEROL plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3912186/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3912186/	Sources: https://pubmed.ncbi.nlm.nih.gov/3912186/
0.4 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 0.4 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.4 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3061311/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3061311/	Sources: https://pubmed.ncbi.nlm.nih.gov/3061311/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2A6 879 CYP1A2 2153 CYP2C19 2057 CYP2E1 1060

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDUyMTU4OSJ9fQ==	no [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDUyMTU4OSJ9fQ==	no [IC50 >10 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDUyMTU4OSJ9fQ==	no [IC50 >10 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDUyMTU4OSJ9fQ==	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDUyMTU4OSJ9fQ==	no [IC50 >10 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNTIxNTg5In19	no [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNTIxNTg5In19	yes [IC50 2 uM]

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNTIxNTg5In19

PubMed

Title	Date	PubMed
Influence of differential expression of acetylcholinesterase in brain and muscle on respiration.	2009-01-01	18977317
Stereoselective inhibition of human, mouse, and horse cholinesterases by bambuterol enantiomers.	2008-09-25	18582854
Effects of acetylcholinesterase and butyrylcholinesterase inhibition on breathing in mice adapted or not to reduced acetylcholinesterase.	2005-01	15652380
Cholinesterases: new roles in brain function and in Alzheimer's disease.	2003-04	12675140
Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease.	1999-01	10027655
Can oral beta2 agonists cause heart failure?	1998-10-03	9798578
Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists.	1998-07	9797754
Therapeutic equivalence between bambuterol, 10 mg once daily, and terbutaline controlled release, 5 mg twice daily, in mild to moderate asthma.	1993-11	8112441
Tremor in healthy volunteers after bambuterol and terbutaline CR-tablets.	1993	8299660
Bambuterol and terbutaline in human cerebrospinal fluid and plasma.	1993	8223836
New lipophilic terbutaline ester prodrugs with long effect duration.	1984-01	24277179

Patents

Sample Use Guides

In Vivo Use Guide

BAMBEC (Bambuterol hydrochloride) Tablets 10 mg. The recommended starting doses are 10 mg–20 mg. The 10 mg dose may be increased to 20 mg if necessary after 1–2 weeks, depending on the clinical effect. In patients who have previously tolerated beta2-agonists well, the recommended starting dose, as well as maintenance dose, is 20 mg. BAMBEC (Bambuterol hydrochloride) oral solution 1mg/ml. The recommended initial dose is 10mg (10ml). The dose may be increased to 20mg (20ml) after 1-2 weeks, depending on the clinical effect. In patients who previously have tolerated oral beta2-agonists well, the recommended initial dose is 20mg (20ml).

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:47:05 GMT 2025` Edited by `admin` on `Mon Mar 31 18:47:05 GMT 2025`
Record UNII	Y1850G1OVC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BAMBUTEROL

Official Name

English

BAMBUTEROL [MI]

Preferred Name

English

bambuterol [INN]

Common Name

English

(±)-5-(2-(TERT-BUTYLAMINO)-1-HYDROXYETHYL)-M-PHENYLENE BIS(DIMETHYLCARBAMATE)

Systematic Name

English

Bambuterol [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QR03CC12